{"product_id":"vygr-five-forces","title":"(VYGR) Voyager Therapeutics, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Voyager Therapeutics, Inc. Porter's Five Forces Analysis helps you quickly assess industry rivalry, buyer and supplier power, substitutes, and the threat of new entrants. The page already shows a real preview of the report, so you can review the content before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized AAV inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. relies on 3 specialized inputs at the same time: adeno-associated virus materials, plasmids, and GMP manufacturing supplies. These are not commoditized, and only a limited number of firms can make them at scale. That supplier concentration gives qualified vendors leverage on price, lead times, and allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. depends on CDMOs for clinical gene-therapy supply, so tight capacity gives suppliers leverage on batch timing, tech transfer, and release specs. That matters more because gene-therapy runs are small, complex, and quality-heavy, and delays can push trials back by quarters. As an early-stage developer with limited internal scale, Voyager has less room to absorb higher per-batch costs or rework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-grade quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Voyager Therapeutics, Inc., suppliers that can meet gene therapy regulatory-grade quality are scarce, so their bargaining power stays high. cGMP-ready viral vector and raw-material providers must deliver tight quality documentation, validation, and comparability support from preclinical work through launch.\u003c\/p\u003e\n\u003cp\u003eThat burden is expensive and slow to replace, so switching suppliers can trigger new studies, re-qualification, and filing updates. In gene therapy, a single weak batch record can delay an IND, BLA, or CMC review, which makes compliant suppliers hard to push on price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and know-how concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces supplier power when a CRO, CDMO, or technology partner owns proprietary methods or specialized analytical know-how. That matters more than raw materials: if a partner controls a critical assay or vector process, Voyager has fewer real substitutes and may need to keep paying for process support and transfer help.\u003c\/p\u003e\n\u003cp\u003eThat dependence is visible in a capital-light model with limited internal manufacturing depth. Voyager reported $255.5 million in cash, cash equivalents, and marketable securities at March 31, 2025, so it can fund partner-heavy work, but it still cannot easily replace scarce IP-driven suppliers once a program is locked into a platform.\u003c\/p\u003e\n\u003cp\u003eIn practice, supplier leverage is highest when know-how is bundled with access to platform rights, technical data, or regulatory history. For Voyager, that can raise switching costs, slow development, and give key partners pricing and timing leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary know-how raises switching costs.\u003c\/li\u003e\n\u003cli\u003eProcess support can be hard to replace.\u003c\/li\u003e\n\u003cli\u003ePartner IP can narrow vendor choice.\u003c\/li\u003e\n\u003cli\u003eCash helps, but not supplier dependence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific labor scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific labor is a tight supplier base for Voyager Therapeutics, Inc. Experienced gene therapy scientists, process engineers, and regulatory specialists are scarce, and the pool is even smaller for AAV and CNS delivery work. In 2025, that scarcity kept hiring competitive and pushed compensation higher, which can raise Voyager Therapeutics, Inc. operating costs and delay programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall pool of AAV experts\u003c\/li\u003e\n\u003cli\u003eCNS delivery skills are rare\u003c\/li\u003e\n\u003cli\u003eHigher pay pressure in 2025\u003c\/li\u003e\n\u003cli\u003eRecruiting takes longer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoyager’s Cash Is Strong, But Scarce AAV Suppliers Keep Costs High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces high supplier power because AAV materials, plasmids, GMP inputs, and CDMOs are scarce and hard to replace. Switching can force revalidation, new studies, and filing updates. Its $255.5 million cash balance at March 31, 2025 helps fund partners, but it does not reduce dependence on scarce, compliant vendors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey driver\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, cash eq., marketable sec.\u003c\/td\u003e\n\u003ctd\u003e$255.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier base\u003c\/td\u003e\n\u003ctd\u003eLimited AAV\/CDMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Voyager Therapeutics, Inc.’s competitive pressure, supplier and buyer power, and entry threats shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Voyager Therapeutics’ strategic pressure points with a clear five-forces snapshot for faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps investors verify Voyager Therapeutics claims quickly with traceable, credible sources that strengthen due diligence and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFew direct buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics is still a development-stage biotech, so it has no broad end-market customer base and no approved product sales. Its buyers are a small group of strategic partners and licensors, and that can give them real pricing and deal-term power. As of FY2024, Voyager still relied on collaboration revenue, with $0 product revenue and $87.6 million in cash, cash equivalents, and marketable securities, which shows how dependent it is on partner-backed funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge pharma leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces strong customer power because its counterparties are large drug makers, not small buyers. Pfizer and Novartis each generated tens of billions in annual sales, while Neurocrine brought about $2.0 billion in 2024 revenue, so they can press hard on milestones, royalties, and option terms. \u003c\/p\u003e\n\u003cp\u003eThat scale lets them demand more control over development speed, data rights, and go-or-no-go decisions. Voyager has less leverage when one partner can fund a program, switch to another platform, or walk away after early-stage results. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers can heavily shape access for Voyager Therapeutics, Inc. gene therapies, especially when one-time prices can reach about $2 million to $3.5 million per treatment. With outcomes often uncertain for years, insurers and health systems may demand rebates, step edits, or prior authorization before coverage. That can cap Voyager Therapeutics, Inc.'s pricing power even if a product wins approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical proof required\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical proof is the main gatekeeper for Voyager Therapeutics, Inc. Customers and partners will want strong efficacy and safety data before they commit capital or support commercialization, because VY-AADC and other assets still face early-stage risk. If results stay mixed, buyers can delay, push for better terms, or walk away.\u003c\/p\u003e\n\u003cp\u003eThat keeps customer bargaining power high. In gene therapy, even one safety signal can reset deal economics, and Voyager Therapeutics, Inc. must prove that its data are durable enough to justify downstream spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly data keeps buyer leverage high.\u003c\/li\u003e\n\u003cli\u003eMixed results weaken deal terms fast.\u003c\/li\u003e\n\u003cli\u003eSafety proof matters as much as efficacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow switching costs for partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces high customer power here because big pharma partners can compare its programs with many outside sources and fund multiple platforms at once, so they are not tied to one collaborator. That lowers switching costs and gives customers room to push for better economics and deal terms.\u003c\/p\u003e\n\u003cp\u003eWith several large partners able to back competing gene therapy and neuro-focused assets, Voyager Therapeutics, Inc. must keep data, milestones, and partner fit strong to defend pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow lock-in, high partner choice\u003c\/li\u003e\n\u003cli\u003eMultiple platforms reduce dependency\u003c\/li\u003e\n\u003cli\u003eBetter data is the key defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoyager Faces Tough Buyer Power From Big Pharma Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces high customer power because its buyers are large pharma partners with stronger balance sheets and many alternatives. With $0 product revenue, $87.6 million in cash, and partner-led funding, Voyager Therapeutics, Inc. must accept tougher milestone, control, and data-rights terms until clinical proof improves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and securities\u003c\/td\u003e\n\u003ctd\u003e$87.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer type\u003c\/td\u003e\n\u003ctd\u003eLarge pharma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVoyager Therapeutics, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Voyager Therapeutics, Inc. Porter’s Five Forces Analysis you’ll receive after purchase—no edits, no placeholders, and no surprises. The document is fully formatted and ready to use immediately upon download. What you see here is the final version, so you can buy with confidence knowing it’s the same file you’ll get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded gene therapy field\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Voyager Therapeutics, Inc. competes in a crowded AAV gene-therapy field where both biotech peers and pharma-backed programs chase the same targets. That lifts rivalry for capital, partners, talent, and trial attention, while also raising the bar for differentiation and speed. With many programs still in clinic and few clear winners, any delay can quickly lose visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS disease competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces heavy rivalry in CNS disease, where Parkinson’s, ALS, Huntington’s, Friedreich’s ataxia, and tauopathy programs all chase high-need markets; Parkinson’s alone affects about 10 million people worldwide. Faster rivals with cleaner Phase 1\/2 data can take mindshare and deal flow, cutting Voyager Therapeutics, Inc.’s first-mover edge. In rare CNS diseases, even small efficacy wins matter, so investors watch readouts and timing as much as science.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform differentiation pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc.'s edge depends on its delivery platform and AAV engineering, but rivals are also improving capsids, tropism, and payload fit. That keeps rivalry intense because buyers compare data quality, safety, and delivery precision, not just IP. In 2025\/2026, the real test is whether Voyager can show cleaner human data and more accurate CNS delivery than other AAV programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech rivalry here is a partnership race, not a launch race. Voyager Therapeutics, Inc. benefits from big-pharma alliances for validation and non-dilutive cash, but rivals are chasing the same deal flow, so bargaining power and funding stay under pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships beat solo commercialization.\u003c\/li\u003e\n\u003cli\u003eBig pharma deals signal technical validation.\u003c\/li\u003e\n\u003cli\u003eRivals also chase non-dilutive funding.\u003c\/li\u003e\n\u003cli\u003eDeal timing can decide market value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh failure and re-entry risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDrug R\u0026amp;D is a churn-heavy arena: only about 10% of candidates reach approval, so rivals often re-enter after setbacks with new constructs or indications. That keeps pressure on Voyager Therapeutics, Inc. even when one program stalls, because fast-followers can quickly reset the fight. Voyager Therapeutics, Inc. must keep funding and advancing its pipeline to defend against better-capitalized entrants and repeat attempts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~10% approval rate keeps rivalry alive\u003c\/li\u003e\n\u003cli\u003eSetbacks often trigger new re-entry\u003c\/li\u003e\n\u003cli\u003eFast-followers can pressure Voyager Therapeutics, Inc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoyager Faces Fierce AAV CNS Rivalry as Trial Data Drive 2025\/2026 Wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces intense rivalry in 2025\/2026 as AAV CNS rivals chase the same rare-disease targets and pharma deals. In a field where only about 10% of drug candidates reach approval, speed, safety, and delivery data decide who wins. Better Phase 1\/2 reads can shift capital and partnerships fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug approval rate\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorldwide Parkinson's cases\u003c\/td\u003e\n\u003ctd\u003e~10 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard-of-care drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard-of-care drugs keep the substitute threat high for Voyager Therapeutics, Inc. Many neurological diseases still rely on symptom control, so familiar pills and injections remain the default choice for doctors and payers. They are widely available, easier to prescribe, and often cheaper than gene therapy, so even weaker efficacy can still win on access and convenience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025-2026, drug makers kept backing small molecules, monoclonal antibodies, antisense oligonucleotides, and RNA-based therapies for many of the same CNS and rare-disease targets Voyager pursues. These substitutes often use simpler manufacturing and more flexible repeat dosing than gene therapy. If they prove safer or cheaper to redose, they can trim demand for Voyager Therapeutics, Inc.’s programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-viral gene approaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-viral gene editing and delivery platforms could pressure Voyager Therapeutics, Inc. because AAV vectors cap payload at about 4.7 kb and usually limit redosing. If newer systems prove durable, allow repeat dosing, and carry larger genes, they could replace some AAV use and weaken Voyager Therapeutics, Inc.’s platform value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupportive care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor several Voyager Therapeutics, Inc. target diseases, patients still default to supportive or palliative care, so the substitute threat stays real even when disease burden is high. WHO says about 56.8 million people need palliative care each year, but only around 14% receive it, showing how entrenched these pathways are. If a novel therapy is expensive, adoption can slow fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupportive care is the default in many severe diseases\u003c\/li\u003e\n\u003cli\u003eHigh price delays switching to new treatments\u003c\/li\u003e\n\u003cli\u003eSubstitute intensity remains meaningful\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrial and access barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrial and access barriers raise Voyager Therapeutics, Inc.'s substitute risk because safety, delivery, or payer hurdles can push patients and physicians toward established options. In rare and neurodegenerative diseases, where many programs still show low success rates, uncertainty makes switching easier when another therapy is already available.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSafer, approved options win when risk rises.\u003c\/li\u003e\n\u003cli\u003eHard delivery lowers physician willingness.\u003c\/li\u003e\n\u003cli\u003eReimbursement gaps push use to incumbents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoyager Faces Heavy Substitute Pressure From Cheaper, More Flexible Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Voyager Therapeutics, Inc. because standard drugs, supportive care, and newer RNA, antibody, and editing platforms can meet many of the same CNS and rare-disease needs. AAV also faces a hard cap of about 4.7 kb, so non-viral delivery can win if it proves safer or easier to redose. WHO says 56.8 million people need palliative care each year, but only about 14% receive it, showing how entrenched low-cost alternatives remain.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalliative care\u003c\/td\u003e\n\u003ctd\u003e56.8M need; 14% receive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV payload\u003c\/td\u003e\n\u003ctd\u003e~4.7 kb limit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGene therapy is capital heavy: GMP manufacturing, clinical trials, and CMC\/regulatory work often push a single program into the tens to hundreds of millions of dollars. That scale keeps smaller would-be entrants from funding proof of concept. Voyager Therapeutics, Inc. benefits because most new players can’t carry that full burn path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAAV gene therapies face tight FDA and global review on safety, biodistribution, durability, and long-term follow-up, with gene-therapy programs sometimes requiring up to 15 years of monitoring. \u003c\/p\u003e\n\u003cp\u003eThat means new entrants need deep CMC, nonclinical, and clinical data, not just a vector idea, which lifts cost and slows entry. \u003c\/p\u003e\n\u003cp\u003eFor Voyager Therapeutics, Inc., that regulatory load acts as a strong barrier and keeps threat of new entrants low. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces a high barrier from scaled viral vector production, which is costly and needs specialized controls to keep yield, purity, and potency consistent. New entrants usually lack validated GMP systems and partner capacity, so they struggle to move from lab batches to reliable commercial supply. That leaves incumbents with proven processes and supply networks in a stronger position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and freedom to operate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces a high entry barrier because gene therapy is crowded with patents on vectors, capsids, payload design, and delivery methods. In 2025, this kind of IP thicket can force new entrants into costly licensing deals or patent fights before they even reach the clinic.\u003c\/p\u003e\n\u003cp\u003eThat raises time, cash burn, and legal risk, which is tough for smaller biotech start-ups. For Voyager Therapeutics, Inc., strong freedom-to-operate positions help protect pricing power and slow would-be rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents cover key gene therapy inputs\u003c\/li\u003e\n\u003cli\u003eLicensing can add major upfront cost\u003c\/li\u003e\n\u003cli\u003eLitigation risk delays clinical entry\u003c\/li\u003e\n\u003cli\u003eStrong IP cuts new-entrant threat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBut innovation can still spawn entrants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoyager Therapeutics, Inc. faces a moderate threat of new entrants because the bar is high, but not closed. Academic spinouts and well-funded biotech startups can still enter with novel capsid engineering or delivery tech, and big pharma can launch its own programs when the science looks strong.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Voyager Therapeutics, Inc. remained a precommercial biotech, so niche innovation still matters more than scale. That keeps entry pressure alive, even if capital needs, scientific know-how, and regulatory risk stop most newcomers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapsid and delivery innovation can open doors\u003c\/li\u003e\n\u003cli\u003eBig pharma can enter fast if promise rises\u003c\/li\u003e\n\u003cli\u003eHigh barriers, but not zero, keep threat moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoyager’s Entry Barriers Stay High on Cost, Time, and Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Voyager Therapeutics, Inc. stays low-to-moderate: AAV programs can require $100M+ to reach early proof, plus up to 15 years of follow-up, and IP\/licensing can add more cost. Voyager Therapeutics, Inc. reported $117.3M cash and investments at 2025 year-end, which is less than the burn needed to fund a full buildout, so capital and scale still block most entrants.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical cost\u003c\/td\u003e\n\u003ctd\u003e$100M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFollow-up\u003c\/td\u003e\n\u003ctd\u003eUp to 15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoyager cash\u003c\/td\u003e\n\u003ctd\u003e$117.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235196576009,"sku":"vygr-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vygr-five-forces.webp?v=1785735755","url":"https:\/\/dcfanalyst.com\/products\/vygr-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}